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Prostaglandin as a Target Molecule for
Pharmacotherapy of Allergic
Inflammatory Diseases
Hiroichi Nagai1
ABSTRACT
The purpose of this review is to summarize the role of prostaglandins (PGs) in allergic inflammation and to
know the value of PGs, as a target molecule for an anti-allergic drug.
PGD2 is the major PG produced by the cyclooxygenase pathway in mast cells. Our and others findings indi-
cate that PGD2 is one of the potent allergic inflammatory mediators and must be a target molecule of anti-
allergic agent. From our data, one of PGD2 receptor antagonists show clear inhibition of airway hypersensitivity
caused by allergic reaction. Concerning the role of PGE2 in allergic inflammation, conflicting results have been
reported. Many experimental data suggest an individual role of each PGE2 receptor, EP1, EP2, EP3 and EP4 in
allergic reaction. Our results indicate the protective action of PGE2 on allergic reaction via EP3. In addition, one
of EP3 agonists clearly inhibits the allergic airway inflammation. These findings indicate the value of EP3 ago-
nists as an anti-allergic agent.
In addition, some investigators including us reported that PGI2 plays an important role for the protection of
the onset of allergic reaction. However, the efficacy of PGI2 analogue as an anti-allergic agent is not yet fully in-
vestigated.
Finally, the role of thromboxane A2 (TxA2) in allergic reaction is discussed. Our experimental results suggest
a different participation of TxA2 in allergic reaction of airway and skin. In this review, the role of PGs in allergic
inflammation is summarized and the value of PGs as a target molecule for developing a new anti-allergic agent
will be discussed.
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Lipid mediators including prostaglandin (PG),
thromboxane (Tx), leukotriene (LT) and lipoxin (LX)
exhibit a wide variety of actions in various cells and
tissues to maintain local homeostasis in the body.
These substances are released immediately after syn-
thesis and act on the cell surface receptors to elicit
their actions. These lipid mediators show strong ac-
tion on mainly cardiovascular, nerve, reproduction
and gastrointestinal systems and inflammatory re-
sponses, as shown in Table 1. In addition to above
systems, recent extensive investigations indicate that
lipid mediators play an important role in immune sys-
tem.1-6
Among the lipid mediators, PGs are the most com-
mon autacoid and there is persuasive evidence that
some PGs contribute to the signs and symptoms of
inflammation and immune system. Most of PGs are
commonly considered as potent proinflammatory me-
diators, actually involved in the pathogenesis of sev-
eral inflammatory diseases such as rheumatoid arthri-
tis, periodontitis and other inflammatory diseases. 7-10
Apart from these findings, much attention has been
paid to allergy, another inflammatory disease related
to immune systems, because the incidence of allergic
patients had increased dramatically in recent dec-
ades. 11-15However the precise role of PGs in allergy
is not fully understood. Therefore, we have attempted
to elucidate the role of PGs in allergy (allergic inflam-
mation) by employing animal models. This review
will provide the reader with an introduction to the role of
PGs in allergic inflammation and thenwill discuss the role
of PG, as a targetmolecule for an anti-allergic drug.
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Table 1 Prostaglandins and thromboxane receptors and physiological actions
ActionCelular signalingReceptorPGs
Platelet aggregate↓, Alergic inflammation↑
Sleep↑
c-AMP↑DP PGD2
Eosinophils↑CRTH2
Smooth muscle↑, Stress↑, Ovatian folicle↑Ca2＋ EP1PGE2
Vasodilation↑, Blood pressure↓c-AMP↑ EP2
Pyrexia↑, Gastric secretion↓, Pain sensation↑c-AMP↓ EP3
Smooth muscle↑Ca2＋↓ 
Patent ductus arteriosus↑, Ossification↑, 
Immune response↓
c-AMP↑EP4
Labor↑, Smooth muscle↑, Intraocular pressure↓IP3/DG↑FPPGF2α
Blood pressure↓, Platelet aggregation↓, Renal blood flow↑c-AMP↑ IPPGI2
Platelet aggregation↑, Smooth muscle↑IP3/DGA TPTxA2
Thrombosis↑c-AMP↓ 
Chemotaxis↑IP3/DG↑ BLT1 LTB4
？c-AMP↓ BLT2 
Airway smooth muscle↑, Eosinophils↑, Permeability↑Ca2＋↑ cys LT1 LTC4, D4, E4
？Ca2＋↑cys LT2
 ↓ ,down regulation; ↑ ,up regulation.
THE ROLE OF PGs IN ALLERGIC INFLAM-
MATION
Identifying a role of any mediator in pathological state
is dependent on the collection of various types of evi-
dence. Often, after the structure of a mediator is iden-
tified, and synthesized, the mediator is given to hu-
mans or experimental animals, to observe whether it
can mimic signs or symptoms of the disease. Then
when quantitative assays are available, efforts are
made to measure it in the biological fluid, to deter-
mine whether it is released during a disease state. In
addition, when the specific antagonists or inhibitors
to the mediator, suppress the symptoms in animal
disease model, the role of mediator is confirmed as a
causative component in the disease.
From these points of view, the role of PGs in aller-
gic inflammation has been examined by many re-
searchers, including us, and various results were ob-
tained. Most researchers agree with the production
of several types of PGs during allergic reaction in hu-
man and experimental animals.16-20 But each re-
searcher has failed to obtain consensus in terms of
the effect of the PG inhibitors on allergic response
and the magnitude of allergic response caused by
each PG. So, in this review, we focused on the experi-
mental results employing PG synthesis inhibitor, in-
domethacin, and PG receptor gene manipulated mice
on allergic reaction in mice.
EFFECT OF INDOMETHACIN
In the first segment of experiment, in order to know
the role of PGs in allergic inflammation, we tried to
establish an allergic airway inflammation model in
mice.21-25 Airway allergic inflammation was caused by
repeated inhalation of aerosolized antigen into sensi-
tized mice. Antigen provocation result in T helper 2
cell (Th2) polarized immune responses and eosino-
philic airway inflammation (Fig. 1). Th2 polarized im-
mune response is characterized by the elevation of
serum IgE and the increase of Th2 cytokines, IL-4, 5
and 13 level and decrease of INF-γ level in bronchial
alveolar lavage fluid (BALF). In addition, the airway
responsiveness to acetylcholine is accelerated by re-
peated antigen provocation. This symptom is similar
to many features of human airway hypersensitivity
(AHR), one of typical asthmatic response.
In the next segment of experiment, to discover the
role of PGs, the effect of indomethacin on this allergic
airway inflammation and AHR was examined. As
shown in Figure 2, indomethacin accelerates the pro-
duction of Th2 cytokines, the accumulation of inflam-
matory cells in BALF and IgE antibody production
(data not shown). The drug also shows the tendency
to accelerate the AHR. These data suggest that the in-
hibition of PG production auguments the allergic in-
flammation. This means the COX products, probably
some PGs, suppress the Th2 dependent allergic in-
flammatory responses. On the other hand, some
other studies so far reported suggest the existence of
a pathological role of PGs in allergic inflamma-
tion.26,27 In fact, the existence of some PGs in allergic
lesion has been recognized and some of them are
able to mimic the symptoms of allergy. Therefore we
carried out further experiments to elucidate the role
of each PG in allergic reaction by employing each PG
receptor gene deficient mice.
PGD2
PGD2 is the major PG produced by the COX pathway
Prostaglandin as a Target for Remedy
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Fig. 1 Changes in airway responsiveness to acetylcholine, immunoglobulin levels in serum, the number of infiltrated cels 
and cytokine levels in bronchial alveolar lavage fluid (BALF) after repeated alergen provocation in mice. Each value repre-
sents the mean ±SEM of 8―12 mice. S-Sal; Injection and inhalation of saline instead of alergen, S-OA; Immunization and in-
halation of ovalbumin (alergen).
＊, ＊＊, ＊＊＊p＜0.05, 0.01 and 0.001, respectively (vs S-OA).
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in mast cells.28 Significant quantities of PGD2 are not
produced by the immunological activation of baso-
phils.29,30 Generally, PGD2 is produced by either L-
type (lipocalin type) or H-type (hematopoetic type)
PGD2 synthetase. L-type PGD2 synthetase exists in
mainly central nervous system and H-type PGD2 syn-
thetase exists in peripheral tissues and immune cells
including mast cells, antigen-presenting cells and Th2
cells. In addition, recent studies have revealed two G
protein-coupled receptor for PGD2, DP and chemoat-
tractant receptor homologous molecule expressed on
Th2 cells (CRTH2). 31,32
Concerning the role of PGD2 in allergic bronchial
asthma, there are some clinical evidence to suggest
the patho-physiological role of PGD2. PGD2 is de-
tected in BALF from asthmatic patients and it con-
stricts human bronchial smooth muscle in vitro.33-35
Despite the recognition of the existence and action of
PGD2 during bronchial asthma, basic research about
the role of PGD2 in allergic inflammation is still lag-
ging.
Therefore, we investigated the role of PGD2 in al-
lergic inflammation by employing DP gene deficient
mice. Consequently, we demonstrated that PGD2
plays a role in an allergic asthma as a mediator.24 Our
results are summarized below briefly. Sensitization
and aerosol challenge of the homozygous mutant DP
gene deficient mice with ovalbumin induced in-
creases in the serum concentration of IgE similar to
those in wild-type mice subjected to this model of al-
lergic asthma. However, the concentration of Th2 cy-
tokines (IL-4 and IL-5) and the extent of lymphocyte
accumulation in the antigen challenged lung of DP
gene deficient mice significantly decreased compared
to those in wild type mice. DP gene deficient mice
showed only marginal infiltration of eosinophils and
failed to develop AHR. Thus, PGD2 functions as a
mast cell derived mediator, to trigger asthmatic re-
sponses. Our results and related evidence regarding
the pharmacological action of PGD2 are summarized
in Table 2.
As described in Table 2, Fujitani et al.36 confirmed
a role of PGD2 in allergic inflammation by employing
L-type PGD2 synthetase gene over-expressed mice.
The overproduction of PGD2 causes an increase in
the levels of Th2 cytokines and chemokines, accom-
panied by the enhanced accumulation of eosinophils
and lymphocytes in the lung. The findings of Fujitani
Nagai H
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Fig. 2 Efect of indomethacin on antigen-induced cytokine production and leukocytes accumulation in BALF in mice. 
Each value represents the mean ±SEM of 6―11 mice. NS-Sal; Injection and inhalation of saline instead of alergen, S-
OA; Immunization and inhalation of ovalbumin (alergen).
＊＊, ＊＊＊p＜0.01 and 0.001, respectively (vs NS-Sal).
†, †† p＜0.05 and 0.01, respectively (vs S-OA).
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Table 2 The role of PGD2 in experimental asthmatic responses in mice
AHRChemokine in BALF
Th2 cytokine 
in BALF
Eosinophils 
in BALFTreatment
↓↓ND  ↓↓  ↓↓ DP gene deficient 
ND ↑↑ (eotaxin)  ↑↑  ↑↑ L-PGDS gene over expression 
↑↑ ↑↑ (MDC)  ↑↑↑↑Inhalation of PGD2
↑↑ ,Increase when compared to control; ↓↓ ,Decrease when compared to control; ND, Not done; BALF, Broncho alveolar lavage flu-
id; AHR, Airway hyperesponsiveness; PGDS, Prostaglandin D2 synthetase; MDC, Macrophase derived chemokine. 
et al.36 and our studies indicate that PGD2 plays an
important role for the accumulation of eosinophils
into allergic lesion. Moreover, Honda et al.37 revealed
the mechanism of PGD2 induced eosinophil infiltra-
tion. They have described the mediation of
macrophage-derived chemokine from airway epithe-
lial cells for PGD2 inducing local eosinophilia.
In addition to DP, recent studies suggest the par-
ticipation of CRTH2 receptor in allergic inflamma-
tion.38,39 Some groups have demonstrated that
CRTH2 selective agonists induce eosinophilic airway
and skin inflammation in animal models.40-44 These
data support the hypothesis that CRTH2 may play a
critical role in allergic inflammation; however, more
Prostaglandin as a Target for Remedy
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Fig. 3 Chemical structure of PGD2 receptor (DP) antagonist and the efect of DP antagonist on antigen-
induced airway hyperesponsiveness in mice. Each experiment consists of the mean ± SE on 5―7 mice.
AUC; area under the curve (range; 31.25―2000 mg/Kg), Ach; acetylcholine.
＊,＊＊,＊＊＊p＜0.05, 0.01 and 0.001, respectively (vs Sal; Student’s test).
＃,＃＃p＜0.05 and 0.01 respectively (vs OA; Student’s t-test).
†, ††p＜0.05 and 0.01, respectively (vs OA; Dunnet’s multiple comparison test).
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data are necessary to clarify the precise role of
CRTH2 in allergic diseases.
From the clinical point of view, whereas extensive
efforts have been made to elucidate the role of PGD2
in allergic diseases, adequate data are not yet forth-
coming. Two of the important references suggest a
close relationship between the onset of allergic
asthma and polymorphism of haematopoietic PGD2
synthetase and DP gene.45,46 These are important
findings to investigate the role of PGD2 in human al-
lergic diseases.
The above-noted clinical and basic researches
stimulate the studies to develop a new anti-DP agent
as a remedy for allergy. Mitsumori et al.47,48 and Ari-
mura et al.49,50 have reported the efficacy of DP an-
tagonist on allergic diseases, especially triggered by
mast cell activation. Using the past findings as a back-
ground, we also tried to examine the effect of DP an-
tagonist on the allergic AHR in mice. Figure 3 indi-
cates the chemical structure of one of a potent DP an-
tagonist and the results of the experiments to meas-
ure the AHR. The DP antagonist showed a clear inhi-
bition of allergic AHR. The increase of eosinophils in
the airway is also inhibited, but the elevation of se-
rum IgE and Th2 cytokine level in BALF are not af-
fected by this agent. In summary, above data suggest
that PGD2 is one of the potent allergic inflammatory
mediators and must be a target molecule of anti-
allergic agent.
PGE2
PGE2 is commonly considered to be a potent proin-
flammatory mediator and is involved in several in-
flammatory diseases including rheumatoid arthritis
(RA). The activity of PGE2 is mediated by four recep-
tors, termed E prostanoid receptors (EP1−4). Activa-
tion of EP2 and EP4 increases intracellular cAMP
whereas the EP1 receptor mediates the elevation of
intracellular calcium. The different isoforms of the
EP3 receptor couple to multiple G proteins producing
either inhibition of adenylate cyclase and calcium mo-
bilization or stimulation of adenylate cyclase activity.
These differences are caused by the condition of em-
ployed cells and circumstances.
Nagai H
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Table 3 Efect of PGE2 on alergic responses
Anti-alergic actions of PGE2
Inhibition of antigen-induced asthmatic responses
(Bronchoconstriction, Airway hyperesponsiveness, 
Eosinophilia, Edema)
1.
Inhibition/augmentation of the immunological release 
of alergic mediators from mast cels
2.
Inhibition of alergic eosinophil recruitment3.
Augmentation of IgE production4.
Regarding the role of PGE2 in allergic reaction,
conflicting results have been reported by some re-
searchers, as shown in Table 3. Parord et al. and
other investigators51-55 have reported that PGE2 in-
hibits the antigen-induced allergic asthmatic re-
sponses, but other researchers56,57 have shown an
augmentation of IgE production and the enhance-
ment of immunological release of mast cell media-
tors.
As for the protective effect of PGE2, when PGE2 so-
lution is inhaled by the asthmatic patients, it prevents
allergen-induced airway response and airway inflam-
mation.52 Other researchers also reported that PGE2
prevents the early and late phase antigen-induced
bronchoconstriction through the relaxation of airway
smooth muscles and inhibition of the release of mast
cell mediators including histamine, leukotrienes and
PGD2.51,53 Moreover, PGE2 protects the allergen-
induced AHR by the reduction of inflammatory cells,
especially eosinophils recruitment. In fact, they indi-
cate that the inhalation of PGE2 by asthmatic patients
markedly attenuates the increase of eosinophils and
metachromatic cells detectable in sputum.
Despite the accumulation of such data, the mecha-
nism of PGE2 action and participating receptors still
remains to be fully elucidated. While there is little evi-
dence about the role of EP1 in allergic reaction, Chan
et al.53-55 have indicated the relationship between EP2
and anti-allergic responses including the relaxation of
airway smooth muscle and the inhibition of histamine
release from mast cells. In addition to EP2, the role of
EP3 in allergic reaction has been extensively stud-
ied.56-58 Our recent study employing EP3 gene defi-
cient mice indicates the importance of EP3 in the re-
cruitment of eosinophils in the lung during antigen-
induced airway inflammation.58 When allergic airway
inflammation is caused by repeated allergen inhala-
tion in EP3 gene deficient mice, allergic airway
eosinophilia, IgE antibody production, Th2 cytokines
(IL-4, 5 and 13) production are accelerated signifi-
cantly when compared to those in wild type mice.
These data suggest that an EP3 agonist can be one of
the ingredients of a new anti-allergic drug. Then we
examined the effect of EP3 receptor selective agonist,
ONO-AE-248, on the allergic airway inflammation in
mice. ONO-AE-248 shows an inhibitory effect on
antigen-induced airway allergic inflammation as indi-
cated in Table 4. The EP3 agonist clearly inhibits the
elevation of airway sensitivity to methacholine and
eosinophilia without affecting IgE antibody produc-
tion. These data indicate that the lack of EP3 gene ac-
celerates the allergic responses and the EP3 agonist
suppresses an allergic inflammation. This probably
means that PGE2 has an anti-allergic inflammatory ac-
tion through EP3 receptor. Regarding the main target
cell for EP3-induced anti-allergic effect, our further
experiments indicate the importance of mast cells. As
indicated in Table 4, passive cutaneous anaphylaxis,
immunological histamine release and IL-13 release
from mast cells are accelerated by the depletion of
EP3 gene. Simultaneously, EP3 agonist clearly inhib-
its the antigen induced histamine release from sensi-
tized mast cells. These data suggest that mast cell is
an effecter cell for the EP3 agonist. Finally, while the
interest on the role of EP4 receptor in allergic reac-
tion is increasing, but unfortunately clear evidence is
stll lacking.
In conclusion, although PGE2 has proinflammatory
properties, it also possesses a bronchodilating and
anti-allergic actions probably through one of four dif-
ferent receptor subtypes. From our data, EP3 agonist
may lead to a new approach for the treatment of aller-
gic diseases.
PGI2
PGI2 is mainly produced by vascular endothelial cells
and prevents platelet aggregation caused by a variety
of stimuli. Some observations indicated the produc-
tion of PGI2 by the local tissues and blood vessels
through an acute allergic inflammation and anaphy-
laxis. In the allergic reaction in lung, produced PGI2
suppresses the generation of leukotrienes and causes
the relaxation of airway smooth muscle.59 These evi-
dences suggest the role of PGI2 in allergic inflamma-
tion and bronchial asthma.
Therefore, we carried out the experiments to trace
the role of PGI2 in allergic reaction by employing al-
lergic airway inflammation model in IP gene lacking
mice.60,61 In IP gene deficient mice, the elevation of
airway eosinophilia, Th2 cytokine production and
leakage of serum albumin into BALF are significantly
augmented by repeated allergen inhalation. These
data suggest that PGI2 may play a suppressive role in
an allergic airway inflammation through IP.
To analyze the mechanism of above response to al-
lergic inflammation in IP gene deficient mice, Th1
and Th2 response of isolated splenocytes were com-
pared in gene deficient mice and wild type mice.
While the IL-4 production by antigen stimulation is
accelerated in the gene deficient mice, IFN-γ produc-
tion is not altered, when compared to wild type mice.
When the anti-CD3 and anti-CD28 induced cytokine
production by isolated CD4+ T cells from non-
sensitized mice were examined, the production of IL-
4 was not altered but IFN-γ production was signifi-
Prostaglandin as a Target for Remedy
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Table 4 Efect of EP3 gene depletion and EP3 agonist, ONO-AE-248, on antigen-induced alergic inflammation in mice
Histamine releaseIgETh2 cytokineEoAHR
↑↑↑↑↑↑ ↑↑ Wild type mice 
↑↑↑↑↑↑↑↑↑↑ ↑↑ EP3 KO mice 
↑↑↑↑↑ ↑↑EP3 agonist ONO-AE-248
↑↑↑ ,Marked increase; ↑↑ ,Significant Increase; ↑ ,Increase; ND, Not done.
Table 5  Efect of IP gene depletion and Beraprost on 
antigen-induced airway inflammation in mice
IgETh2cytokineEoAHR
↑↑↑↑ ↑↑  ↑↑ Wild type mice 
↑↑↑↑↑↑ ↑↑↑  ↑↑ IP-KO mice 
↑↑↑↑↑↑Beraprost
 ↑↑↑ ,Marked increase; ↑↑ ,Significant Increase; 
 ↑ ,Increase.
cantly decreased in the T cells from IP gene deficient
mice. These data suggest the possibility that PGI2
suppresses the antigen-induced activation of Th2
cells and stimulates the activity of resting Th1 cells.
Furthermore, Jaffar et al.62 have reported one poten-
tial mechanism supporting our findings. They have
inferred that the anti-allergic action of PGI2 is closely
related to the production of T cell derived IL-10 which
is known to suppress Th2 immunity. Thus, PGI2 may
show an immunomodulating action through a produc-
tion of IL-10 via IP.
In addition to above-noted sub-chronic airway in-
flammation, we conducted another experiment to in-
vestigate the role of PGI2 in the chronic airway aller-
gic inflammation, airway wall remodeling in mice by
using IP gene deficient mice.61 Airway wall remodel-
ing model was produced by daily inhalation of anti-
gen for 3 weeks after the systemic immunization in
mice. In this model, apparent airway eosinophilia,
goblet cell hypertrophy and fibrosis under airway epi-
thelial cell were observed. These changes are depend
on Th2 cells, eosinophils and TGF-β1. By employing
this experimental model, we confirmed a suppressive
role of PGI2 in chronic airway inflammation, airway
wall remodeling in mice. Regarding to chronic inflam-
matory responses, Strauon et al.63 have reported that
the production of connective tissue growth factor and
collagen synthesis by TGF-β1 stimulated fibroblast
were clearly inhibited by PGI2. These data suggest
that PGI2 plays a role in the production of collagen di-
rectly.
From these data PGI2 can be considered as a use-
ful source to tap up a remedy for allergic diseases, we
examined the effect of Beraprost, a PGI2 analogue, on
the experimental airway allergic inflammation. As
shown in Table 5, Beraprost indicated the suppres-
sion of airway allergic eosainophilia and Th2 cytokine
production, but did not show the inhibition of AHR
and IgE production. Moreover, the inhibition pattern
of Beraprost is not dose related. To confirm the effect
of PGI2 agonists, the effect of two other PGI2 ana-
logues on allergic inflammation were studied, and the
results were similar to those of Beraprost. These data
indicate the difficulty in developing a new anti-allergic
drug from PGI2 analogues and the necessity of addi-
tional studies to confirm the suitability of PGI2 ana-
logue as a remedy for allergic diseases.
OTHER EICOSANOIDS
TxA2 is not a PG but an important another cyclooxge-
nase derived eicosanoid. Many evidences suggest a
role of TxA2 in allergic inflammation.63-65 Various re-
ports also indicate the release of TxA2 during allergic
reaction and TxA2 causes a potent bronchoconstric-
tion in vitro and in vivo.66-68 In addition, the TxA2 re-
ceptor, TP, exists in immune competent organs in-
cluding thymus and spleen.69,70 Moreover, recent
studies concerning human subject polymorphism in
the TP gene are associated with atopic dermatitis.71
Using such background information as pegs, we in-
vestigated the role of TxA2 in allergic inflammation
by employing TP gene deficient mice.72 Our examina-
tion was carried out in two different types of experi-
mental models. An allergic inflammation was caused
in the airway and skin by repeated local antigen
provocation. Surprisingly, our findings from two ex-
periments indicate a reversal of results in terms of
causing an allergic inflammation in the skin and lung.
Our data suggest that TxA2 may play a pathological
role in the airway inflammation but it acts as a sup-
pressive factor in the skin. These data indicate the ex-
istence of different allergic mechanism in the lung
and skin regarding the role of TxA2, and also suggest
a difficulty in developing a new anti-TxA2 agent as an
anti-allergic drug.
CONCLUSION
This review describes the role of PGs in allergic in-
flammation and the value of PGs as a target molecule
for developing a new anti-allergic agent. Several in-
vestigators, including us, have shown that some PG
and anti-PG agents are effective in the therapy of ex-
perimental allergic disease models. Our studies em-
ploying PG receptor and TxA2 receptor gene defi-
cient mice suggest that EP3 or IP agonists and DP or
TP antagonist would be expected to be a remedy for
allergic diseases. IP agonist and TP antagonist, how-
ever, indicates the partial efficacy in an allergic
Nagai H
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model. Our data indicate that an EP3 agonist and DP-
antagonist have more possibility as a remedy for al-
lergic airway inflammation. Further studies regarding
more effective agent and precise mechanism of PGs
in allergic inflammation are needed for discovering a
new anti-allergic drug.
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